Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:02:23 2023-02-03 pm EST
339.08 USD   +2.53%
02/03Wells Fargo Adjusts Eli Lilly's Price Target to $360 From $375, Maintains Equal Weight Rating
MT
02/03Lilly to Participate in Guggenheim Oncology Conference
PR
02/03Morgan Stanley Adjusts Price Target on Eli Lilly to $455 From $440, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société ELI LILLY AND COMPANY
02/03Lilly to Participate in Guggenheim Oncology Conference
PR
02/02HighTide Therapeutics Appoints Dr. Tianwei Ma as VP of Discovery Research
AQ
02/02Eli Lilly And : Q4 2022 Financial Workbook
PU
02/02Lilly : Q4 Earnings Snapshot
AQ
02/02Eli Lilly And : Q4 2022 Lilly Press Release
PU
02/02Eli Lilly And : Q4 2022 Lilly Presentation
PU
02/02Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline ..
PR
01/27U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Rev..
PR
01/26Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold ..
PR
01/24Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangl..
PR
01/19U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Appro..
PR
01/19Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Annou..
PR
01/11Eli Lilly And : Estimated acquired ipr&d and development milestone charges
PU
01/11University Of Hawai'i : National award to advance peptide drug development
AQ
01/04Lilly to Participate in the J.P. Morgan Healthcare Conference
PR
2022Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery..
AQ
2022Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Co..
AQ
2022Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diab..
AQ
2022Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable..
AQ
2022Lotus acquires Alimta in Taiwan from Lilly
AQ
2022Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable..
PR
2022Eli Lilly And : 2023 Guidance Presentation
PU
2022Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
PR
2022Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend
PR
2022Boehringer Ingelheim - Phase III trial demonstrated Jardiance is the first SGLT2 inhibi..
AQ
2022Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistica..
PR
2022Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ D..
AQ
2022Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Dis..
PR
2022Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptoma..
PR
2022Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement
PR
2022Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium
PR
2022Lilly to Participate in Evercore ISI HealthCONx Conference
PR
2022Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform
PR
2022Akouos Investor Alert By The Former : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
PR
2022ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and Finan..
AQ
2022Eli Lilly And : Q3 2022 Lilly Presentation
PU
2022Lilly : Q3 Earnings Snapshot
AQ
2022Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progres..
PR
2022Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufac..
PR
2022Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announ..
PR
2022Lilly Declares Fourth-Quarter 2022 Dividend
PR
2022Eli Lilly & Co : Other Events (form 8-K)
AQ
2022Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adu..
PR
2022FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adu..
PR
2022Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to R..
AQ
2022Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase ..
PR
2022Lilly Announces Details of Presentations at ESMO Congress 2022
PR
2022Eli Lilly And : 2022 CDP Climate Change Report
PU
2022Eli Lilly And : 2022 CDP Water Security Report
PU
2022Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
PR
2022Lilly to Participate in Citi's 17th Annual BioPharma Conference
PR
2022Direct Relief Delivers Seven-Week Supply of Long-Acting Insulin to Ukraine, Donated by ..
AQ
2022Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Offic..
PR
2022Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
AQ
2022Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce In..
PR
2022Biden team, Eli Lilly condemn new Indiana abortion ban
AQ
2022ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and Finan..
AQ
2022Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
PR
2022Eli Lilly And : Q2 2022 Financial Workbook
PU
2022Eli Lilly And : Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New..
PU
2022Eli Lilly And : Q2 2022 Lilly Press Release
PU
2022Lilly : Q2 Earnings Snapshot
AQ
2022Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines an..
PR
2022Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Annou..
PR
2022Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ong..
PR
2022Lilly Declares Third-Quarter 2022 Dividend
PR
2022Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
AQ
2022Eli Lilly And : Lilly Diabetes & Obesity ADA Update Presentation
PU
2022Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab..
PR
2022Lilly to Participate in Goldman Sachs Global Healthcare Conference
PR
2022Lilly to build two new US manufacturing sites
AQ
2022Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana
PR
2022Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Cli..
PR
2022Lilly to Participate in UBS Global Healthcare Conference 2022
PR
2022Eli Lilly & Co : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ELI LILLY AND COMPANY